Method for reprogramming somatic cells to generate induced pluripotent stem cells
By introducing 3D suspension culture and an early MET strategy into human cell reprogramming, the problem of low iPSC generation efficiency in existing technologies has been solved, achieving efficient and stable iPSC production suitable for large-scale production.
Patent Information
- Application Number
- PCT/CN2024/093355
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-17
- Filing Date
- 2024-05-15
- Publication Date
- 2024-11-21
AI Technical Summary
Existing technologies struggle to generate a sufficient number of induced pluripotent stem cells (iPSCs) in a short time during human cell reprogramming, and the reprogramming results of mouse cells cannot be directly applied to human cells, resulting in low efficiency and inconsistency.
We employed an early reprogramming strategy combining 3D suspension culture with mesenchymal-epithelial transition (MET) to form iPSC spheres by transferring them to 3D suspension culture after 2D culture, thus avoiding conventional clonal selection, simplifying the procedure and improving stability.
It generates higher quality and quantity of stable iPSCs in a shorter time, improving reprogramming efficiency and uniformity, and is suitable for large-scale production.
Smart Images

Figure PCTCN2024093355-FTAPPB-I100001 
Figure PCTCN2024093355-FTAPPB-I100002 
Figure PCTCN2024093355-FTAPPB-I100003
Abstract
Description
Methods for reprogramming somatic cells to generate induced pluripotent stem cells Technical Field
[0001] The present invention relates to a somatic cell reprogramming method, in particular to a method for inducing the generation of pluripotent stem cells by reprogramming somatic cells (especially human cells) in 3-dimensional (3D) suspension culture. Background Art
[0002] Human embryonic stem cells (ESCs) derived from blastocysts exhibit pluripotency, such as the potential for self-renewal and the ability to differentiate into cells of all germ layers. 1 The pluripotency characteristics of embryonic stem cells are expected to be used to generate different cell derivatives for research or clinical applications. Subsequent progress in this field led to the discovery of induced pluripotent stem cells (iPSCs), in which terminally differentiated somatic cells can be restored to a pluripotent state similar to ESCs through nuclear reprogramming mediated by OCT4, KLF4, SOX2, and c-MYC (OKSM). 2 The revolutionary discovery of human iPSCs avoids many ethical issues associated with the generation of human ESCs, and their similarity to human ESCs makes iPSCs a potential alternative for cell therapy and regenerative medicine applications. 3,4 .
[0003] To date, different reprogramming methods and advances for generating iPSCs have been reported, aiming to improve the safety, stability, quality, and quantity of iPSCs to meet the current clinical requirements for the manufacture of iPSC cell derivatives. For example, non-integrating viral / mRNA / episomal / protein reprogramming methods have been developed to generate transgene-free iPSCs to replace traditional integrating lentiviral / retroviral reprogramming methods. 2,5-10 In addition, it has been reported that modifications to the reprogramming process, such as by adding hydrogels to provide a 3D reprogramming microenvironment, can enhance reprogramming. 11、12 In iPSC culture, three-dimensional (3D) culture systems have been developed, in which iPSCs are cultured in the form of spheroids using large-scale bioreactors; compared with traditional two-dimensional (2D) culture systems (i.e., monolayer culture), 3D culture systems have been shown to be equally good at maintaining pluripotency and are capable of producing iPSCs on a larger scale. 13-16 .
[0004] Although iPSC technology has proven promising in the fields of cell therapy and regenerative medicine, generating sufficient numbers of iPSCs from somatic cells for therapeutic purposes remains a lengthy process. A reprogramming method with greater iPSC yield in a shorter timeframe is needed.
[0005] SUMMARY OF THE INVENTION
[0006] Conceptually, integrating 3D reprogramming and 3D culture systems is a promising strategy to increase iPSC yield. However, feasibility studies on this integration are extremely limited and currently focus on mouse fibroblasts. There have been no reports on integrating reprogramming with 3D culture systems on human somatic cells. See, for example, doi:10.1038 / nmeth.1939 (“Derivation, expansion and differentiation of induced pluripotent stem cells in continuous suspension cultures“, 2016), which discloses that transfected mouse fibroblasts were cultured in suspension at the very early stage of reprogramming (approximately 2-3 days) after transduction of OKSM reprogramming factors to produce induced pluripotent stem cells. The authors pointed out that due to the lack of clonal selection, although the iPSC population was obtained by suspension culture, the population was heterogeneous and contained partially reprogrammed cells that would affect the subsequent differentiation potential of the population.
[0007] Furthermore, studies have shown that although mouse and human cells can be reprogrammed using the same combination of factors, the reprogramming process differs significantly between the two species. Reprogramming of mouse cells can typically be completed in one or two weeks, while human cells can take up to a month. Furthermore, human iPSCs have significantly lower conversion efficiencies and different characteristic morphologies compared to mouse iPSCs. Furthermore, studies have shown that the actual regulatory networks of pluripotency factors diverge significantly between the two species during the early stages of reprogramming. These differences make it difficult to extrapolate reprogramming findings obtained in mouse cells to human cells. See, e.g., https: / / doi.org / 10.1186 / s12864-018-5326-1 (“Comparison of reprogramming factor targets reveals both species-specific and conserved mechanisms in early iPSCs reprogramming", 2018); and https: / / reactome.org / PathwayBrowser / #R-HSA-452723&FLG=O43474, DOI: 10.3180 / REACT_200812.1.
[0008] To solve the above problems, the present inventors are committed to the reprogramming research of human cells. It is surprising to find that in the relatively early stage of reprogramming that undergoes mesenchymal-epithelial transition (MET), the introduction of 3D suspension culture is a more effective strategy for integrating reprogramming with 3D culture on human cells. On this basis, the present inventors have established the 3-dimensional reprogramming method of the present invention. Although it is not desired to be bound by any theory, it is believed that in the relatively early stage of reprogramming of MET, the integration of 3D suspension culture will only allow stable reprogrammed cells to continue to proliferate and produce iPSC spheres. Thus, based on the method of the present invention, there is no need for conventional clone selection to exclude stubborn non-reprogrammed cells and unstable partially reprogrammed cells in the culture, thereby effectively simplifying the procedure. At the same time, as shown in the disclosed embodiments, compared to conventional 2D reprogramming methods, the method of the present invention allows for the scalable production of more stable iPS cells with better differentiation potential in a shorter time window.
[0009] Therefore, in a first aspect, the present invention provides a method for generating iPSCs by reprogramming human or non-human primate somatic cells, the method comprising: culturing reprogrammed iPSC spheres from reprogramming intermediates in 3D suspension culture. Herein, the method is also referred to as the "3D reprogramming method of the present invention." Herein, iPSCs generated according to the 3D reprogramming method of the present invention are also referred to as "3D reprogrammed iPSCs."
[0010] In some embodiments, the 3D reprogramming method according to the present invention comprises the following steps:
[0011] (a) performing a reprogramming treatment on somatic cells, so that the somatic cells are contacted with reprogramming factors;
[0012] (b) culturing the treated somatic cells of step (a) under 2D culture conditions for a period of time sufficient to obtain a reprogramming intermediate, wherein the reprogramming intermediate is characterized in that at least 20%, 30%, 40% or 50% of the cells are iPSC precursor cells that have undergone MET transformation;
[0013] (c) harvesting the reprogramming intermediates of step (b), and culturing them in liquid culture medium under 3D suspension culture conditions to form reprogrammed iPSC spheres,
[0014] Wherein, the somatic cells are somatic cells from non-human primates or humans.
[0015] In some embodiments, in the reprogramming intermediate, the iPSC precursor cells that have undergone MET transformation lose the morphological characteristics of the original somatic cells and exhibit a MET morphology characterized by domed, dense cell colonies and optionally an increased nuclear-to-cytoplasmic ratio. Preferably, the iPSC precursor cells that have undergone MET transformation express the pluripotency markers TRA-1-60 and / or SSEA3.
[0016] In some embodiments, step (c) of the method according to the present invention comprises harvesting the reprogramming intermediates on about day 7 to about day 21 of reprogramming, more preferably on about day 10 to about day 18 of reprogramming, for example, on day 10, day 11, day 12, day 13, day 14, day 15, day 16, day 17, day 18.
[0017] In some embodiments, the somatic cells used in the methods of the present invention are somatic cells or cell lines from adult individuals. In some preferred embodiments, the somatic cells are human blood cells, e.g., human PBMCs. In other preferred embodiments, the somatic cells are human fibroblasts.
[0018] In some embodiments, in step (c) of the method according to the present invention, the 3D suspension culture is a stirred or rotating suspension culture system, such as a roller bottle, an orbital shaker or a bioreactor.
[0019] In some embodiments, step (c) of the method of the present invention further comprises, after a period of suspension culture, passaging the formed cell spheroids for at least one generation, preferably at least 2 or 3 generations, to obtain a stable iPS cell population.
[0020] In some embodiments, the reprogramming factors used in the present invention are reprogramming transcription factors, and step (a) includes introducing one or more reprogramming factors or nucleic acids encoding the reprogramming factors into the somatic cells to increase the expression or protein amount of the reprogramming factors in the somatic cells.
[0021] In some embodiments, step (a) of the method of the present invention comprises delivering the reprogramming factors to the somatic cells in the form of an integrating virus or a non-integrating virus, or in the form of mRNA, an episomal plasmid, or a protein. In some preferred embodiments, step (a) comprises delivering the reprogramming factors to the somatic cells using a non-integrating virus, particularly a Sendai virus vector.
[0022] In some embodiments, the one or more reprogramming factors used in the method of the present invention include or consist of at least three or at least four of Klf4, c-Myc, Oct3 / 4, Sox2, Nanog and Lin28; and preferably, the one or more reprogramming factors include or consist of Oct3 / 4, Sox2, c-Myc and Klf4.
[0023] In some embodiments, step (c) of the method according to the present invention comprises culturing the reprogramming intermediate in suspension at a rotation speed of 30-100 rpm, preferably at a rotation speed of about 70 rpm. Preferably, step (c) of the method according to the present invention is performed using iPSC maintenance medium (preferably StemScale PSC suspension medium) for the 3D culture.
[0024] In a second aspect, the present invention provides a method for maintaining or expanding 3D reprogrammed iPSCs in a 3D culture system. The method can be scaled up to accommodate large-scale iPSC production.
[0025] In some embodiments, the method for maintaining or expanding 3D-reprogrammed iPSCs according to the present invention comprises:
[0026] (i) obtaining reprogrammed iPSC spheres from autologous cells using the 3D reprogramming method according to the present invention; and
[0027] (ii) maintaining or expanding the iPSCs in 3D suspension culture conditions.
[0028] In some embodiments, the method further comprises a cell passaging step after step (i) and before step (ii).
[0029] In some embodiments, the passaging step comprises passaging the cells when the size of the iPSC sphere reaches between 300-500 μm.
[0030] In some embodiments, in step (ii) of the method, the maintenance culture of the iPSC includes passage cells once every 4-6 days. Preferably, a ROCK inhibitor, preferably Y27632, is added to the culture medium during the first 12-48 hours (preferably 24 hours) of cell passage. In some embodiments, the cell passage includes generating a single cell or a cell mass of no more than 200 cells from an iPSC sphere and reseeding. Preferably, an iPSC single cell suspension is generated from an iPSC sphere by enzymatic hydrolysis (e.g., Accutase enzyme) for cell passage.
[0031] In a third aspect, the present invention provides a method for producing downstream cell-derived products, the method comprising: obtaining 3D-reprogrammed iPSCs by the 3D reprogramming method of the present invention, and using the iPSCs to produce downstream cell-derived products. Since the 3D reprogramming method according to the present invention can provide a high yield of 3D-reprogrammed iPSCs, it is suitable for mass production of downstream cell-derived products.
[0032] Advantages of the method of the present invention
[0033] By integrating 3D culture into the reprogramming process, higher quality iPSCs can be generated.
[0034] The present method integrates 3D culture into the reprogramming process, allowing for large-scale expansion during reprogramming; compared to 2-dimensional reprogramming and culture methods, higher iPSC cell yields can be generated in a shorter time. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] FIG1 shows the morphological changes of reprogrammed cells in 2D culture monitored under a phase contrast microscope on day 0 (A), day 7 (B), and day 35 (C) of reprogramming.
[0036] Figure 2 shows morphological assessment and cell counts of 3D-reprogrammed iPSC spheres. (A) Representative images comparing iPSCs generated via 2D reprogramming with iPSCs generated via 3D reprogramming. (B) Comparison of iPSC yields from 2D and 3D reprogramming methods.
[0037] Figure 3 shows representative immunofluorescence staining of 2D-reprogrammed iPSCs (top) and 3D-reprogrammed iPSCs (bottom), immunostained for pluripotency markers OCT4, SOX2, and TRA-160, and nuclear staining with DAPI. (A) Peripheral blood mononuclear cells (PBMCs) and (B) fibroblasts were used as the starting somatic cell sources for reprogramming.
[0038] FIG4 shows the relative expression of Sendai virus transgenes (A) and pluripotency markers (B) in somatic cells corresponding to 3D-reprogrammed iPSCs and Sendai virus controls as detected by RT-PCR.
[0039] Figure 5 shows the tri-lineage differentiation potential of 3D-reprogrammed iPSCs. (A) Endoderm, mesoderm, and ectoderm differentiation efficiency of 3D-reprogrammed iPSCs compared to 2D-reprogrammed iPSCs. (B) Representative FACS analysis of endoderm, mesoderm, and ectoderm derived from 2D- and 3D-reprogrammed iPSCs.
[0040] Detailed Description of the Invention
[0041] definition
[0042] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. For the purposes of the present invention, the following terms are defined below.
[0043] The term "about" when used in conjunction with a numerical value is meant to encompass the numerical value within a range having a lower limit that is 5% less than the specified numerical value and an upper limit that is 5% greater than the specified numerical value.
[0044] When used in conjunction with two or more alternatives, the expression "and / or" should be understood to mean any one of the alternatives or a combination of any two or more of the alternatives.
[0045] As used herein, the term "comprises" or "includes" means including the elements, integers or steps mentioned, but does not exclude any other elements, integers or steps. In this article, when the term "comprises" or "includes" is used, unless otherwise indicated, it also covers the situation consisting of the elements, integers or steps mentioned.
[0046] As used herein, "expression markers" or "markers" can be used to determine the identity of a cell type. Certain informative DNA sequences of cell-specific genes can be transcribed into mRNA and typically subsequently translated into proteins (gene products thereof) that perform specific functions in the cell. The expression of such markers can be detected and quantified at the RNA level or protein level by methods known in the art to characterize the cells. Markers that can be used to characterize pluripotent stem cells and three germ layer (mesoderm, endoderm, and ectoderm) cell lineages are well known in the art.
[0047] As used herein, the term "pluripotency" or "stemness" refers to the ability of a cell to produce offspring and, under appropriate conditions, differentiate into cell types of the three germ layers (endoderm, mesoderm, and ectoderm). The pluripotency of a cell population can be established using standard assays recognized in the art, such as the ability to form teratomas in 8-12 week old SCID mice or the tri-lineage differentiation method described in the Examples. Pluripotent cells can also be detected by identifying other pluripotent stem cell characteristics. Such characteristics include, but are not limited to, the expression or absence of certain combinations of molecular markers. Cell markers for human pluripotent stem cells can be selected from one or more (preferably at least four) of the following: SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, ALP, PODXL, SOX2, E-cadherin, EPCAM, KLF4, LIN-28A, SOX11, SALL2, PRDM14, OCT4 (POU5F1), REX1, and NANOG. The cell morphology associated with pluripotent stem cells is also a characteristic of pluripotent stem cells. Typically, on a 2-dimensional culture matrix, pluripotent stem cells typically grow as flat colonies with clear edges, and cells grow densely in the colonies. Under a phase contrast microscope, the morphology of pluripotent cells can be distinguished from that of somatic cells, for example, fibroblasts have a characteristic long spindle shape and a significantly larger cell volume.
[0048] In this article, induced pluripotent stem cells (also referred to as "iPS" cells in this article) refer to cells generated from somatic cells by expressing or inducing the expression of a group of cytokines, and having the ability to differentiate into various cell types that exhibit characteristics associated with the cell lineages of the three germ layers (endoderm, mesoderm, and ectoderm). Typically, iPSCs (i.e., iPS cells) have typical pluripotent stem cell morphology, are capable of self-renewal, have tri-lineage differentiation capacity, and express a combination of multiple pluripotency markers (e.g., OCT4, NANOG, SOX2, and PDOXL).
[0049] As used herein, "somatic cell" refers to any somatic cell in a mammal other than germline cells (spermatogonia and oocytes). Examples of such cells include differentiated cells and their precursors and ancestral cells. Examples of differentiated cells include, but are not limited to, cells from various tissues (e.g., bone marrow, skin, skeletal muscle, adipose tissue, and peripheral blood). Exemplary cell types include, but are not limited to, fibroblasts, hepatocytes, myoblasts, neurons, osteoblasts, and T cells. In the present invention, any non-pluripotent cell (e.g., a poorly differentiated cell or a highly differentiated cell) can be used as a starting somatic cell to produce iPSCs. In some embodiments, the somatic cell is a "non-embryonic somatic cell," meaning that the somatic cell does not exist in or is obtained from an embryo and is not produced by in vitro proliferation of such cells. In some embodiments, the somatic cell is an "adult somatic cell," meaning that the cell exists in or is obtained from an adult individual that is not an embryo or fetus, or is produced by in vitro proliferation of such cells. For example, the somatic cell can be an adult somatic cell or a cell from an adult. Somatic cells can acquire unlimited proliferation capacity by immortalization, such as by increasing the level of telomere end transcriptase. In some embodiments, the somatic cells are differentiated somatic cells or immortalized cell lines thereof, including somatic cells or immortalized cell lines thereof from fetal, neonatal, juvenile or adult primate individuals, including human individuals. In some embodiments, the somatic cells used in the present invention are selected from the group consisting of bone marrow cells, epithelial cells, endothelial cells, fibroblasts, hematopoietic cells, hepatocytes, keratinocytes, intestinal cells, mesenchymal cells, myeloid precursor cells, and spleen cells. In other embodiments, the somatic cells used in the present invention are cells that can proliferate and differentiate into certain cell types, selected from, for example, blood stem cells, brain stem cells, and liver stem cells. In some embodiments, the somatic cells used in the present invention are selected from the following cells from humans or non-human primates: bone marrow cells, epithelial cells, endothelial cells, fibroblasts, peripheral blood mononuclear cells, hematopoietic cells, keratinocytes, hepatocytes, intestinal cells, mesenchymal cells, bone marrow precursor cells, spleen cells, and CD34-positive cells collected from placental blood. In some preferred embodiments, somatic cells are human fibroblasts (preferably skin fibroblasts) or human blood cells (preferably human PBMC). For different application purposes, such as treatment needs, the somatic cells used for the inventive method can be autologous cells separated from human individuals to be treated with cell therapy or allogeneic cells relative to the individual. Moreover, in some embodiments, somatic cells can be cells genetically modified by recombinant methods. For the reprogramming purpose of the present invention, it should be understood that suitable somatic cells are receptive, or can become receptive using methods known in the art, that is, can take in reprogramming factors or the genetic material encoding reprogramming factors, or increase the expression of reprogramming factors in cells under reprogramming treatment.Those skilled in the art are familiar with the morphological characteristics of various somatic cells and can readily determine the time point at which somatic cells begin reprogramming by monitoring the time point at which somatic cells lose their characteristic morphology. The state of somatic cell reprogramming to pluripotent stem cells can also be determined by monitoring the upregulation of expression of at least one pluripotency marker.
[0050] In this article, "reprogramming" refers to the process of reversing non-pluripotent (including mature, specialized or differentiated) cells into induced pluripotent stem cells. Reprogramming is a step-by-step process involving multiple steps. Studies have shown that the reprogramming process involves a variety of cell states that appear one after another, which can be roughly divided into an initial phase, a mature phase and a stable phase. In the initial phase, the reprogrammed cells do not express or very rarely express pluripotency markers, and are unstable and reversible; in the mature phase, some pluripotency markers are expressed; and in the stable phase, the reprogrammed cells express a combination of multiple pluripotency markers and can continue to divide to produce undifferentiated iPS cells. When somatic cells cultured in vitro lose the typical morphology of the original somatic cells, it can be determined that the somatic cells have begun to be reprogrammed to a pluripotent state. See, Philos Trans R Soc Lond B Biol Sci. 2018Jul 5;373(1750):20170213, "Pluripotent stem cells: induction and self-renewal", doi:10.1098 / rstb.2017.0213.
[0051] Herein, “reprogramming factor” refers to a factor or a combination of factors that promotes the reprogramming of somatic cells to obtain a pluripotent state. Typical reprogramming factors are transcription factors with reprogramming functions, also referred to herein as “reprogramming transcription factors” or “transcription factors”. Available reprogramming transcription factors are known in the art, see, for example, https: / / doi.org / 10.1038 / nrm.2016.8 (“A decade of transcription factor-mediated reprogramming to pluripotency”). The following table gives some examples of commonly used reprogramming transcription factors and lists their Ensemble Gene ID and Uniprot ID, from which relevant nucleotide sequence and amino acid sequence information can be obtained. The present invention also contemplates functional variants, homologs, orthologs and paralogs of these factors.
[0052] Table A: Some exemplary reprogramming transcription factors
[0053] In this article, " reprogramming process " refers to that somatic cells are placed under conditions that make them reprogram to induced pluripotent stem cells.Various methods for somatic cell reprogramming are known in the art.Typically, somatic cell reprogramming involves increasing the amount of reprogramming factors (for example, reprogramming transcription factors) in somatic cells, and then culturing the cells under specific conditions to promote the loss of differentiation markers and the acquisition of pluripotency markers.In this article, " reprogramming day 0 " refers to the day when somatic cells begin to receive reprogramming process (for example, transgenic reprogramming factor transfection or transduction).
[0054] In this article, when the reprogramming factor is a transcription factor, the expression "increasing the amount of the reprogramming factor" or "increasing the expression or protein amount of the reprogramming factor" are used interchangeably and refer to an increase in the expression and / or expression product amount of the reprogramming factor (e.g., a somatic cell that receives reprogramming treatment, such as a fibroblast or PBMC) relative to a control cell (i.e., a corresponding cell that has not received reprogramming treatment). In some embodiments, the amount of the reprogramming transcription factor in the target cell (e.g., a somatic cell into which an exogenous nucleic acid encoding the transcription factor is introduced) is increased by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more relative to a control cell (e.g., a corresponding somatic cell into which the exogenous nucleic acid is not introduced). Any method that can be used to increase the amount of a transcription factor is within the contemplation of the present invention, including methods for increasing the transcription amount, transcription speed or transcription efficiency of a transcription factor in a cell, increasing the translation and protein yield of a transcription factor, and increasing the stability or activity of a transcription factor.
[0055] As used herein, the term "exogenous" in relation to a protein, gene, nucleic acid or polynucleotide in a cell or organism refers to an artificial introduction of the protein, gene, nucleic acid or polynucleotide into the cell or organism, and when the cell or organism has an endogenous counterpart of the protein, gene, nucleic acid or polynucleotide, the introduced protein, gene, nucleic acid or polynucleotide is present in the cell or organism in a form different from that of the endogenous counterpart (e.g., located in a different position, or located in a non-natural nucleic acid construct, or connected to a different flanking nucleic acid sequence). Thus, a transcription factor (e.g., SOX2) introduced into a somatic cell of interest by recombinant means is exogenous with respect to the somatic cell of interest, as distinct from the transcription factor (e.g., endogenous SOX2) naturally present in the somatic cell. In some embodiments, the exogenous nucleic acid is present in the cell of interest in an extrachromosomal form, e.g., in the form of an episomal vector.
[0056] Herein, Kruppel-like factor 4 (KLF4), also referred to as GKLF, is a member of the KLF family of zinc finger transcription factors. KLF4 is involved in the regulation of cell proliferation, cell differentiation, apoptosis, and somatic cell reprogramming, and plays an important role in maintaining the stemness of embryonic stem cells and preventing their differentiation. An example of KLF4 can be found in Uniprot accession number O43474.
[0057] Herein, Oct4, also referred to as POU5F1 or Oct3 / 4, refers to the transcription factor encoded by the POU5F1 gene. Oct4 has a domain homologous to the POU domain and is crucial for the self-renewal and stemness maintenance of undifferentiated embryonic stem cells. Oct4 is also commonly used as a molecular marker for undifferentiated cells. An example of Oct4 can be found in Uniprot accession number Q01860.
[0058] In this article, SOX2 refers to a member of the SRY-related HMG-box (SOX) transcription factor family. The transcription factor SOX2 forms a trimeric complex with OCT4, controlling the expression of numerous genes involved in embryonic development and participating in the regulation of embryonic development and cell fate determination. An example of SOX2 can be found in Uniprot accession number P48431.
[0059] In this article, PODXL (also known as podocalyxin) refers to a negatively charged salivary mucin that belongs to the CD34 family of proteins. PODXL carries numerous post-translational epitopes that are responsible for multiple pluripotency surface markers, including TRA-1-60, TRA-1-81, GCTM2, GP200, and mAb84.
[0060] As used herein, "Nanog" refers to the homeobox protein NANOG. This protein is a transcriptional regulator involved in the proliferation and self-renewal of inner cell mass and embryonic stem (ES) cells. An example of NANOG can be found in Uniprot accession number Q9H9S0.
[0061] Throughout this article, "Lin28" refers to an RNA-binding protein found during embryogenesis. It has two paralogs: LIN28A and LIN28B. It has been reported that somatic cells can be reprogrammed to pluripotency through a combination of OCT4, SOX2, NANOG, and LIN28A or LIN28B. An example of LIN28A can be found in Uniprot accession number Q9H9Z2; an example of LIN28B can be found in Uniprot accession number Q6ZN17.
[0062] As used herein, "KOS" refers to a transgene encoding the reprogramming factors hKLF4, hOct3 / 4, and hSox2, present in a polycistronic format on a single vector (e.g., a Sendai virus vector). When using a Sendai virus-based reprogramming system containing KOS, an additional hKLF4 viral expression vector can be added to compensate for the lack of viral polymerase activity due to the polycistronic structure of KOS, thereby enhancing reprogramming efficiency.
[0063] As used herein, "c-Myc" refers to a member of the Myc family of proto-oncogenes that encodes a regulatory gene for a transcription factor. POU5F1, SOX2, c-Myc, and KLF4 are members of the Yamanaka quadrifactor family. Combined, these factors have been shown to be sufficient to reprogram differentiated cells into iPS cells. An example of c-Myc can be found in Uniprot accession number P01106.
[0064] As used herein, the term "Tra-1-60" refers to the monoclonal antibody Tra-1-60, or, depending on the context, to a glycotope pluripotency marker on PODXL specifically recognized by the antibody. In some embodiments according to the present invention, the expression of the epitope recognized by the Tra-1-60 antibody can be used to assess the pluripotency state of 3D reprogramming intermediates.
[0065] In this article, "SSEA3" refers to the pluripotent stem cell-associated cell surface glycosphingolipid antigen - stage-specific embryonic antigen 3.
[0066] In this article, "mesenchymal-epithelial transition" (abbreviated as MET or MET conversion) refers to an important event that occurs in the early stage of reprogramming during the in vitro reprogramming of somatic cells into induced pluripotent stem cells (iPSCs), in which the reprogrammed cells undergo mesenchymal-epithelial transition and acquire stemness or pluripotency. In this article, relative to MET conversion, "epithelial-mesenchymal transition" (abbreviated as EMT) refers to the somatic cell epithelial-mesenchymal transition event that occurs before MET during the in vitro reprogramming of somatic cells into induced pluripotent stem cells (iPSCs).
[0067] As used herein, the term "MET morphology" or "MET phenotype" refers to cells undergoing MET transformation during in vitro reprogramming, losing the morphology of the original somatic cells, and exhibiting a cell morphology or phenotype in 2-dimensional culture that is different from typical iPSCs and is characterized by dome-shaped, dense cell colonies and optionally an increased nuclear-to-cytoplasmic ratio.
[0068] In this article, "iPSC morphology" or "iPSC phenotype" means that the reprogrammed cells exhibit the typical in vitro cultured iPSC morphology, forming compact, flat multicellular colonies in 2D culture, with clear colony boundaries, and the cells in the colony are round, with a high nuclear-to-cytoplasmic ratio, and prominent nucleoli. Healthy iPSC colonies will fuse seamlessly, with multiple layers of cells in the center, forming tight cell clusters under phase contrast microscopy. However, as is known in the art, iPSC colonies grown on different substrates may exhibit slightly different morphologies. For example, in Vitronectin XF TM The growth may be tighter and rounder, while the use of The colonies that do grow may be more dispersed and irregular in shape. On both matrices, spontaneous differentiation of iPSCs is characterized by loss of colony boundary integrity, the appearance of irregular cell morphology areas within a colony, or the emergence of other cell types.
[0069] Herein, "reprogramming intermediate" refers to a reprogrammed cell culture from which stable iPSC colonies have not yet been established.
[0070] As used herein, “reprogramming intermediates that undergo MET” (or “MET reprogramming intermediates” for short) refer to reprogramming intermediates that contain at least 20%, 30%, 40%, or 50% iPSC precursor cells that undergo MET transformation, and thus exhibit MET morphology or MET phenotype. The morphological changes of reprogrammed cells can be monitored by phase contrast microscopy in 2-dimensional culture to identify unreprogrammed original somatic cells, reprogramming intermediates that undergo MET, and stable iPSC cells. Reprogrammed cells that enter MET transformation acquire stemness or pluripotency and express some pluripotency markers. Therefore, MET reprogramming intermediates can also be identified by monitoring changes in the expression levels of one or more specific pluripotency markers and reprogramming factor transgenes in reprogrammed cells, and optionally comparing them with unreprogrammed original somatic cells and stable iPSC cells. In MET reprogramming intermediates, in some preferred embodiments, at least 20%, 30%, 40%, or 50% of the reprogrammed cells have increased expression of the pluripotency markers TRA-1-60 and / or SSEA3 compared to the original somatic cells; however, preferably, less than 20%, less than 30%, less than 40%, or less than 50% of the reprogrammed cells are positive for at least four pluripotency markers, including SOX4, PODXL, OCT4, and NANOG; and / or have higher expression levels of transgenic reprogramming transcription factors than stable iPSCs. Generally, for human somatic cells, in vitro reprogrammed somatic cells enter the MET transition between days 5 and 21 of reprogramming; however, as will be appreciated by those skilled in the art, the specific time of MET entry will depend on the somatic cell type used and the specific culture conditions. In the case of human fibroblasts, MET reprogramming intermediates suitable for 3D suspension culture of the present invention can be obtained, for example, between days 10 and 21, more preferably around days 13 to 18.
[0071] As used herein, "MET conversion rate" refers to the proportion of cells in a reprogramming intermediate that undergo MET conversion and exhibit a MET morphology or phenotype. Preferably, the cells undergoing MET conversion also express one or both of the pluripotency markers TRA-1-60 and SSEA3. The MET conversion rate of reprogramming intermediates used for 3D suspension culture affects iPS cell yield. While not wishing to be bound by theory, it is believed that if the MET conversion rate is too low, the human cells in the reprogramming intermediate will be in a very unstable state, thereby reducing the efficiency of obtaining totipotent iPS cells. The MET conversion rate of reprogramming intermediates suitable for 3D suspension culture can be determined by one skilled in the art based on the specific cell type and culture conditions used, according to the teachings of this disclosure. In some embodiments, the MET conversion rate suitable for the methods of the present invention is at least 20%, 30%, 40%, or 50%. In other embodiments, the MET conversion rate suitable for the methods of the present invention is at least 50%, 55%, 60%, 65%, 70%, 75%, or 80%.
[0072] As used herein, "adherent" means that cells adhere to a vessel, for example, to a sterile plastic (plastic-coated) cell culture dish or flask in the presence of an appropriate culture medium.
[0073] Herein, 2-dimensional culture (also referred to as 2D culture) refers to a culture method in which cells are attached to the wall, grow in two dimensions, and form a cell monolayer. In the 3D reprogramming method of the present invention, somatic cells should be cultured under 2D culture conditions for at least a period of time before entering 3-dimensional culture to enter the MET state. 2D culture methods and conditions suitable for reprogramming of various human cells are well known in the art and can be used in the method of the present invention to obtain the MET reprogramming intermediates of the present invention. For example, somatic cells to be induced to pluripotency can be cultured on feeder cells (such as MEF); alternatively, they can be grown directly on a solid culture surface (e.g., a culture plate). Culture media suitable for culturing different cell types are well known in the art and are commercially available. For example, fibroblasts can be cultured using Essential 6 or Essential 8 from ThermoFisher.
[0074] In this article, 3D culture (also referred to as 3D culture) refers to a culture method in which cells are grown in three dimensions to form cell clusters or specific tissue structures. Typical 3D cultures include those that rely on and those that do not rely on solid / semi-solid supports. 3D cultures that rely on supports include, for example, cells that are seeded on a pre-prepared three-dimensional scaffold (usually a polymer scaffold) for growth. 3D cultures that do not rely on supports include hanging drop cultures, cultures in low-adhesion microplates, and cultures in rotary bioreactors.
[0075] In this article, 3D suspension culture refers to the cultivation of single cells or small cell clusters in liquid culture medium under constant agitation to enable them to expand in a non-adherent manner and grow in three dimensions.
[0076] In this article, "stable iPSCs" and "completely reprogrammed cells" are used interchangeably to refer to iPS cells that show complete characteristics of ES cells and are able to continue dividing to produce undifferentiated iPSCs. Because reprogramming is a complex process involving multiple events, only a few cells can complete the process. Partially reprogrammed cells that have not completed the process may also exhibit ES-like morphology, but the epigenetic state of these cells retains traces of somatic cell characteristics and may subsequently differentiate or die. See, for example, https: / / doi.org / 10.1038 / nrm.2016.8. Therefore, typically, iPSC precursor cells that enter MET still require several cell cycles to establish stable iPSC colonies. Stable iPSCs and cells in the early stages of reprogramming (almost no pluripotency marker expression) or mature stages (only some pluripotency markers are expressed) can be distinguished by the expression or expression level of pluripotency markers in reprogrammed cells. In addition, it has also been recognized that although the expression of exogenous reprogramming factors should continue for a sufficiently long time during the reprogramming process, the generation and stabilization of iPSCs depends on the silencing of transgenic reprogramming factors in the late reprogramming period, approximately at the time point when the cell fate is directed to the ES-like cell state. Therefore, the stability of iPSC colonies can also be examined by monitoring the silencing of the transgene. Typically, stable iPSCs are capable of self-renewal / capable of generating cell types of the three germ layers and express the pluripotency markers OCT4, NANOG, SOX2, and PODXL; and have silenced expression of transgenic reprogramming factors. In this article, a "stable iPSC population" or "stable iPSC colony" means that at least 90% or more of the cells in the cell population or colony are stable iPS cells that exhibit typical morphological characteristics and pluripotent stem cell marker expression characteristics of iPSCs.
[0077] In this article, "2-dimensional conventional reprogramming program" refers to a 2-dimensional cell culture program that relies on adherent culture and cell passage, starting from somatic cell reprogramming to the formation of stable iPSC. Taking fibroblasts and PBMC as examples, typically, in such programs involving transfection of nucleic acids encoding reprogramming factors, the sequence includes the following steps: on the 0th day of reprogramming, that is, the day of transfection, reprogramming factors are introduced into adherent cultured somatic cells by transduction or transfection; After culturing for several days (e.g., about 5-7 days), the cells are re-seeded on a culture plate, continued to be adhered to the wall, and continuously cultured for 1-4 weeks or longer, until cell colonies appear and grow to a size suitable for passage. In this reprogramming process, typically, a few days after transfection (e.g., 5-12 days), initial cell colonies will appear on the re-seeded culture plate, and as the culture progresses, the colony volume gradually increases until most of the surface area of the culture vessel is covered. However, only a small fraction of these colonies contain fully reprogrammed cells, and colonies containing partially reprogrammed cells are difficult to distinguish from colonies containing fully reprogrammed cells by naked eye. Therefore, in conventional 2D-iPSC reprogramming procedures, after obtaining the initial colonies, subsequent iPSC clone selection and / or multiple 2D subcultures are usually required to ensure the growth of authentic iPSC cells and exclude non-pluripotent cells such as unreprogrammed cells, dead cells, differentiated cells, etc., in order to obtain "stable" iPSC cultures.
[0078] Herein, 2D-iPSC refers to iPSC obtained through conventional 2D reprogramming procedures. Herein, 3D-iPSC refers to iPSC obtained through the 3D reprogramming procedures of the present invention.
[0079] In this article, "downstream cell-derived products" refer to other iPS cells or differentiated cells produced by expansion and / or differentiation of iPSCs generated by reprogramming, for example, cardiomyocytes, macrophages, hepatocytes, neurons, and their precursor cells. Such cell-derived products can be transferred to the source mammalian individual of the somatic cells used to generate the iPSCs. In other words, the somatic cells used in the method of the present invention can be autologous cells. Alternatively, the somatic cells used in the method of the present invention can be allogeneic relative to the mammalian individual to which the downstream cell-derived products are administered. Preferably, the somatic cells used in the method of the present invention are derived from the patient to be treated with the cell-derived product, that is, they are autologous cells.
[0080] The various aspects of the present invention are described in further detail below.
[0081] 3-dimensional reprogramming method of the present invention
[0082] In conventional 2D-iPSC reprogramming process, it is generally believed that the colony that first appears after reprogramming is passed down too early, and cell aggregates will become non-adherent, which not only affects iPSC yield, but also cells may begin to differentiate, so that other cell types and different forms appear. However, in the research devoted to the reprogramming and 3D culture of human body cells, the inventors have surprisingly found that in the early stage of 2-dimensional reprogramming of human body cells undergoing mesenchymal-epithelial transition (MET), 3D suspension culture is introduced, which can effectively achieve the integration of reprogramming and 3D culture, while obtaining the generation and amplification of stable iPSC. Thus, the inventors have established the 3D reprogramming method of the present invention applicable to human body cells and non-human primate somatic cells.
[0083] Therefore, in a first aspect, the present invention provides a method for generating iPSCs by reprogramming somatic cells of a human or non-human primate, the method comprising the following steps:
[0084] (a) reprogramming human cells to increase the expression or protein amount of one or more reprogramming factors in the somatic cells;
[0085] (b) culturing the treated somatic cells of step (a) under 2D culture conditions for a period of time sufficient to obtain a reprogramming intermediate, wherein the reprogramming intermediate is characterized in that at least 20%, 30%, 40% or 50% of the cells are iPSC precursor cells that have undergone MET transformation;
[0086] (c) harvesting the reprogrammed intermediates of step (b) and culturing them in a liquid culture medium under 3D suspension culture conditions to form reprogrammed iPSC spheres. In the following description, various aspects of the present invention are described using human cells as an example. It should be understood that these aspects of the present invention also encompass any embodiment in which non-human primate somatic cells are substituted for human cells.
[0087] Reprogramming intermediates
[0088] Mesenchymal-epithelial transition (MET) and epithelial-mesenchymal transition (EMT) are terms well known in the art. It is known in the art that differentiated somatic cells can be reprogrammed into pluripotent cells in vitro through successive EMT-MET conversion events, and blocking MET in this early reprogramming process of somatic cells will weaken the reprogramming efficiency (https: / / doi.org / 10.1038 / s41556-018-0195-z, “Mesenchymal–epithelial transition in development and reprogramming”, 2019). Reprogrammed cells that undergo MET may exhibit gene expression changes characteristic of MET, for example, downregulation of mesenchymal gene expression and / or upregulation of epithelial gene expression. In addition, during the MET process, the cytoskeleton is reshaped, causing the reprogrammed cells to lose the morphology of the source somatic cells. In 2D in vitro culture, somatic cells that undergo MET transformation typically exhibit characteristic MET morphology or phenotype, growing into dense cell colonies with a dome-like appearance that is distinct from typical iPSCs. The cells in the colonies have a round shape and a high nuclear-to-cytoplasmic ratio similar to iPS cells, but are larger in size.
[0089] According to the method of the present invention, reprogramming intermediates having such MET morphology or MET phenotype can be advantageously expanded in 3D suspension culture and generate stable iPSC spheres. Therefore, in some embodiments, the method of the present invention comprises reseeding such reprogramming intermediates (i.e., MET reprogramming intermediates) cultured in 2 dimensions into liquid culture medium and culturing them under 3D suspension culture conditions for a period of time sufficient to form iPSC spheres.
[0090] In some embodiments, the reprogramming intermediate according to the present invention can be a mixture of partially reprogrammed cells, fully reprogrammed cells, and unreprogrammed cells and / or differentiated cells. In some embodiments, the reprogramming intermediate used in the method of the present invention has a MET conversion rate of at least 20%, 30%, 40% or 50%, wherein the reprogrammed cells of the percentage are iPSC precursor cells that undergo MET conversion. In some embodiments, the reprogramming intermediate has a MET conversion rate of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90%. In some preferred embodiments, the reprogramming intermediate has a MET conversion rate of 20-80%. In some further preferred embodiments, the reprogramming intermediate has a MET conversion rate of 50-90%. In some further preferred embodiments, the reprogramming intermediate has a MET conversion rate of 60%-80%.
[0091] In some embodiments, the iPSC precursor cells that have undergone MET conversion in the reprogramming intermediate exhibit a MET morphology or phenotype, and preferably further express one or both of the pluripotency markers TRA-1-60 and SSEA3.
[0092] The time for obtaining a suitable MET reprogramming intermediate may be different according to different somatic cell types. In some embodiments, at about the 7th day to about the 21st day of reprogramming, the MET reprogramming intermediate is harvested, for example, at the 10th day, the 11th day, the 12th day, the 13th day, the 14th day, the 15th day, the 16th day, the 17th day, the 18th day, the MET reprogramming intermediate is harvested. In some embodiments, the harvest time of the MET reprogramming intermediate is about the 10th day to about the 21st day of reprogramming, about the 13th day to about the 18th day, or about the 13th day to about the 15th day. In some embodiments, the somatic cells are human fibroblasts or human blood cells, and at about the 13th day to about the 21st day of reprogramming, preferably the 13-18th day or the 13-15th day, the MET reprogramming intermediate is harvested.
[0093] Delivery of reprogramming factors
[0094] In order to obtain the MET reprogramming intermediates of the present invention, the known reprogramming treatments of the present invention can be used to increase the expression or protein amount of the reprogramming transcription factors in the target somatic cells, thereby achieving the purpose of transformation.
[0095] The induction of pluripotency was first demonstrated in mouse cells in 2006 (Yamanaka et al., 2006) and in human cells in 2007 (Yu et al., 2007; Takahashi et al., 2007) by reprogramming somatic cells with the introduction of pluripotency-associated transcription factors. Recently, the use of various small-molecule reprogramming factors has also been proposed (see, https: / / doi.org / 10.1038 / s12276-020-0383-3, 2019, “Small-molecule-mediated reprogramming: a silver lining for regenerative medicine”). Methods that can be used to reprogram human somatic cells to produce induced pluripotent stem cells (iPSCs) include, but are not limited to, methods disclosed in the following documents: U.S. Patent Application No. 20090246875, published U.S. Patent Application No. 2010 / 0210014; published U.S. Patent Application No. 20120276636; U.S. Patent No. 8,058,065; U.S. Patent No. 8,129,187; U.S. Patent No. 8,268,620; PCT Publication No. WO 2007 / 069666 A1 and U.S. Patent No. 8,268,620, which are hereby incorporated by reference herein. The above-mentioned pluripotency induction methods are all applicable to the methods of the present invention to obtain the reprogramming intermediates of the present invention.
[0096] In some embodiments, thus, step (a) of the present method includes reprogramming human cells to contact somatic cells with reprogramming factors that induce pluripotency. In some embodiments, the reprogramming factor is a small molecule compound. In other embodiments, the reprogramming factor is a transcription factor. In some further embodiments, small molecule reprogramming factors are combined with reprogramming transcription factors for use in the method of the present invention to improve the efficiency of reprogramming. Exemplary small molecule reprogramming factors include, but are not limited to, agents that inhibit H3K9 methylation or promote H3K9 demethylation; agents that inhibit H3K4 demethylation or promote H3K4 methylation; agents that inhibit histone deacetylation or promote histone acetylation; L-type calcium channel agonists; activators of the cAMP pathway; DNA methyltransferase (DNMT) inhibitors; nuclear receptor ligands; GSK3 inhibitors; MEK inhibitors; TGFβ receptor / ALK5 inhibitors; HDAC inhibitors; Erk inhibitors; ROCK inhibitors; FGFR inhibitors; and PARP inhibitors. In still other embodiments, the small molecule reprogramming factor is selected from the group consisting of: a GSK3 inhibitor; a MEK inhibitor; a TGFβ receptor / ALK5 inhibitor; an HDAC inhibitor; an Erk inhibitor; and a ROCK inhibitor.
[0097] In some more typical embodiments, in the reprogramming method according to the present invention, reprogramming transcription factors are used to produce pluripotent stem cells from somatic cells. In such embodiments, somatic cells are reprogrammed to dedifferentiation or pluripotent state, generally involving increasing the expression or protein amount of reprogramming factors (including transcription factors) in somatic cells. Any transcription factor related to pluripotency can be used as a reprogramming factor according to the present invention. The relevant transcription factors may comprise one or more of the following, or consist of or consist essentially of one or more of the following factors: Oct-3 / 4, Cdx-2, Gbx2, Gsh1, HesX1, HoxA10, HoxA11, HoxB1, Irx2, Isl1, Meis1, Meox2, Nanog, Nkx2.2, Onecut, Otx1, Oxt2, Pax5, Pax6, Pdx1, Tcf1, Tcf2, Zfhx1b, Klf-4, Atbf1, Esrrb, Gcnf, Jarid2, Jmjd1a, Jmjd2c, Klf-3, Klf-5, Mel-18, Myst3, Nac1, REST, Rex-1, Rybp, Sall4, and all1, Tif1, YY1, Zeb2, Zfp281, Zfp57, Zic3, Coup-Tf1, Coup-Tf2, Bmi1, Rnf2, Mta1, Pias1, Pias2, Pias3, Piasy, Sox2, Lef1, Sox15, Sox6, Tcf-7, Tcf7l1, c-Myc, L-Myc, N-Myc, Hand1, Mad1, Mad3, Mad4, Mxi1, Myf5, Neurog2, ngn3, Olig2, Tcf3, Tcf4, Foxc1, Foxd3, BAF155, C / EBPβ, mafa, Eomes, Tbx-3; Rfx4, Stat3, Stella, and UTF-1. The mammalian and human cDNA sequences and amino acid sequences of these reprogramming factors can be found in the Ensemble GENE database and the UniProtKB database. In some embodiments, the transcription factors used in the methods of the invention comprise, consist of, or consist essentially of one or more of the following: OCT4, SOX2, KLF4, and MYC (OSKM); SOX2, KLF4, and OCT4 (SKO); OCT4, SOX2, KLF4, and GLIS1 (OSKG); OCT4, SOX2, NANOG, and LIN28 (OSNL); or OCT4, SOX2, KLF4, c-MYC, NANOG, and LIN28 (OKSMNL). In some preferred embodiments, the transcription factors comprise, consist of, or consist essentially of one or more of the following: OCT4, SOX2, KLF4, and MYC.Preferably, the transcription factors include all four of these factors (OSKM), or variants thereof.
[0098] In some embodiments, step (a) of the method of the present invention includes reprogramming human cells to increase the expression or expression level of one or more reprogramming transcription factors in the somatic cells. In some embodiments, the reprogramming process includes introducing a combination of multiple reprogramming transcription factors into the target somatic cells, or introducing one or more polynucleotides encoding the transcription factor combination. In embodiments using encoding polynucleotides, it is understood that one or more expression cassettes can be used to achieve the expression of the transcription factor combination. For example, when using an expression cassette to express multiple polypeptides, a polycistronic expression cassette can be used. It is also understood that one or more vectors containing the polynucleotides or expression cassettes can be used to introduce the one or more polynucleotides or the one or more expression cassettes into the target somatic cells. Examples of vectors include, but are not limited to, viral and non-viral vectors. When using a viral vector for reprogramming, preferably, the viral vector is a non-integrating, replication-defective vector (for example, a viral vector that has removed some or all of the viral nucleic acids required for encoding viral replication). In addition, non-viral vectors, such as plasmids, liposomes, nanoparticles and other DNA molecule delivery methods, are also considered in the present invention. In some embodiments, the present invention uses viral vectors to deliver reprogramming factors to target somatic cells. To this end, a nucleic acid construct containing nucleic acid encoding the reprogramming factor can be inserted into a non-replicating or replication-defective viral genome and packaged into infectious viral particles. After the viral vector transfects or transduces the cell, the viral genome containing the construct will enter the cell and, depending on the type of virus, may or may not integrate into the cell genome.
[0099] In this article, "non-integrating viral vector" means that the viral vector cannot integrate the genetic material it carries into the genome of the host cell. After infecting the host cell, the genome of such viral vector exists in the transduced cell as a non-replicating episome, thereby avoiding the risk of insertional mutagenesis caused by integration. Examples of non-integrating viral vectors include, but are not limited to, adenovirus, adeno-associated viral vectors, Sendai virus, poxvirus, modified non-integrating lentivirus, etc. Viral vectors can be constructed and modified according to methods known in the scientific literature to increase their efficiency and safety in reprogramming applications. For example, specific mutations, such as temperature-sensitive mutations, can be introduced into some viral genes in the viral genome, so as to control the residence time or expression silencing of the viral vector or the transgene it carries in the host by changing the cell culture temperature.
[0100] In some embodiments of the inventive method, the nucleic acid encoding the transcription factor required for reprogramming is delivered to the somatic cell by one or more vectors. Each transcription factor can be introduced into the somatic cell as a nucleic acid construct comprising a transgenic polynucleotide encoding the factor effectively connected to a heterologous promoter. A constitutive strong promoter can be used to provide the expression of a majority of transcription factors in a polycistronic form. An expression cassette under the control of a separate promoter can also be provided, on a vector or a plurality of separate vectors, to provide the expression of a majority of transcription factors. The heterologous promoter for the inventive method can be selected based on the desired transcription factor expression level and / or the silencing speed of the promoter. In some embodiments of the inventive method, at least 3 or 4 transcription factors are introduced into the somatic cell, and according to the factor type and somatic cell type delivered, those skilled in the art can test and easily determine the best factor delivery ratio.
[0101] In some embodiments, the nucleic acid sequence encoding the transcription factor protein is introduced into somatic cells via a plasmid. In some embodiments, the plasmid comprising the nucleic acid encoding one or more transcription factors can be an additional body type plasmid. In one embodiment, the nucleic acid sequence encoding the transcription factor protein is introduced into somatic cells via a vector (e.g., a viral vector or a non-viral vector). Preferably, the vector is a viral vector, for example, a retroviral vector, a lentiviral vector, an adenoviral vector or a Sendai virus vector. Preferably, the vector is a non-integrating viral vector. In some embodiments, the expression or protein amount of the reprogramming transcription factor in somatic cells is increased by transducing or transfecting somatic cells with the vector.
[0102] Although it is preferred to use exogenous nucleic acids to increase the expression or protein amount of reprogramming factors in somatic cells according to the method of the present invention, it is also possible to consider using a transcription activation system to increase the expression of one or more transcription factors in vivo, such as the CRISPR / Cas9 system for gene expression regulation.
[0103] In some preferred embodiments of the method according to the present invention, in step (a), Sendai virus is used to deliver reprogramming factors. Sendai virus (also referred to as SeV) is an attractive vector that can be used to deliver reprogramming factors (including, but not limited to, OCT4, SOX2, KLF4 and CMYC (OKSM)) into somatic cells to generate iPSCs. The virus is non-pathogenic to humans and has an RNA genome that can persist in the cytosol, thereby eliminating the risk of reprogramming factors or viral genes being integrated into the genome. In addition, the application of Sendai virus vectors is already mature in reprogramming somatic cells into iPSCs, and commercial kits for this purpose are readily available, including but not limited to, CytoTune available from Invitrogen. TM-iPS Sendai virus reprogramming kit. The long-term presence of reprogramming factors and reprogramming vectors in induced iPSC cells is not desirable due to its carcinogenic risk and impact on iPSC analysis. However, the advantage is that the Sendai virus vector, as a non-integrating vector, generally disappears after several generations as the cells are passaged, thereby preventing the reprogramming factors from persisting in iPSC cells for a long time. In addition, temperature-sensitive Sendai viruses have been developed. After the reprogramming factors are introduced into the somatic cells to be reprogrammed, the residual reprogramming vectors and the expression of vector transgenes can be removed from the induced iPSCs by temperature changes at the desired stage as needed. In order to monitor the acquisition of vector-free iPSCs, in some embodiments, a combination of primers containing Sendai virus genomic sequences and transgene-specific primers can be designed to specifically detect the expression level of transgenes carried on the Sendai virus vectors.
[0104] The somatic cells that can be used for reprogramming are not particularly limited. Generally, differentiated somatic cells, including cells from fetuses, newborns, young or adult mammals, such as primates, including humans, are somatic cells suitable for the method of the present invention. Such somatic cells can be reprogrammed into induced pluripotent stem cells by the 3-dimensional reprogramming method of the present invention. In some embodiments, the somatic cells according to the present invention are selected from: bone marrow cells, epithelial cells, endothelial cells, fibroblasts, peripheral blood mononuclear cells, hematopoietic cells, keratinocytes, hepatocytes, intestinal cells, mesenchymal cells, bone marrow precursor cells and spleen cells from humans. In some preferred embodiments, the somatic cells are fibroblasts or peripheral blood mononuclear cells (PBMCs) derived from humans.
[0105] In some particularly preferred embodiments of the methods according to the present invention, the reprogramming treatment according to the present invention comprises transducing human cells (e.g., human PBMCs and fibroblasts) with Sendai vectors encoding KOS, hc-Myc and hKlf4 (preferably at a multiplicity of infection of 1:1:0.1-1.5, such as 5:5:3 or 5:5:6).
[0106] 2-dimensional culture for obtaining reprogramming intermediates
[0107] After the reprogramming process (e.g., obtaining cells transduced with reprogramming factors), the method of the present invention further comprises culturing the reprogrammed cells under two-dimensional culture conditions for an appropriate period of time to obtain suitable reprogramming intermediates (i.e., step (b) of the method of the present invention). Depending on factors such as the somatic cell source and culture conditions used, the two-dimensional culture period can vary; for example, for human fibroblasts and PBMCs, it can be approximately 7-21 days.
[0108] There is no particular limitation on the two-dimensional culture method applicable to step (b) of the method of the present invention. For example, the reprogrammed cells obtained in step (a) of the present invention can be cultured according to any two-dimensional culture method for reprogrammed cells known in the art.
[0109] In some embodiments, the reprogrammed cells are cultured by contacting with feeder cells. Exemplary feeder cells include, but are not limited to, fibroblasts, e.g., mouse embryonic fibroblast (MEF) cells. Methods for culturing cells on feeder cells are known in the art.
[0110] In some embodiments, the reprogrammed cells are cultured in the absence of feeder cells. The cells can be directly attached to a solid culture surface (e.g., a culture plate), for example, via an artificial matrix. Exemplary matrices include, but are not limited to, laminin, fibronectin, vitronectin, proteoglycans, entactin, collagen, collagen I, collagen IV, collagen VIII, heparan sulfate, Matrigel, TM Or any combination thereof. However, it will be appreciated by those skilled in the art that this is a non-limiting list and that other molecules may be used to attach cells to a solid surface. Methods for initially attaching a matrix to a solid surface are known in the art.
[0111] In some embodiments involving transfection or transduction of nucleic acids encoding reprogramming factors into somatic cells, the sequence of steps (a) and (b) of the method of the present invention comprises the following operations:
[0112] - about several days before transfection or transduction (depending on the somatic cells used, for example, about 2-3 days), the somatic cells are seeded in a culture vessel (for example, a well of a 6-well plate), and the cells are cultured to ensure that the cells are completely attached and spread;
[0113] On day 0 of reprogramming, i.e., the day of transfection, a nucleic acid encoding a reprogramming factor is introduced into the somatic cells by transduction or transfection, and the transfected cells are cultured in a somatic cell culture medium for several days (depending on the somatic cells used, for example, about 5-10 days);
[0114] - Re-seeding the cells onto culture plates with or without feeder cells and culturing them to adhere to the plate. During this period (e.g., on the second day after seeding), the culture medium is replaced with iPSC culture medium and culture is continued until MET-like cell colonies appear;
[0115] - Optionally, detecting cell colonies to obtain MET reprogramming intermediates.
[0116] 3D culture of reprogramming intermediates
[0117] When the majority of cells (eg, at least 50%, 70%) of the cell population constituting the reprogramming intermediate appear to be iPSC precursor cells with MET transformation, the intermediate is harvested for three-dimensional suspension culture according to the present invention.
[0118] Suspension culture applicable to the present invention includes, but is not limited to, oscillation culture (agitation culture), rotation culture (rotating cultures), shake culture (Shake cultures), rotation culture (Spinning cultures) and stirred culture (Stirred cultures). In this article, suspension culture does not include, and cells are embedded or encapsulated or attached in or on a specific solid or semi-solid matrix, the suspension culture carried out. Such solid or semi-solid matrix includes but is not limited to, gel, hydrogel, high molecular polymer scaffold, microcarrier etc. In this article, 3D suspension culture does not relate to before suspension culture, cells are embedded, encapsulated or attached to the pretreatment within or on a support or matrix. Therefore, it is understandable that the suspension culture carried out in the form (such as gel microbeads) of cells embedded in semi-solid / solid matrices such as gel / hydrogel or in the form (such as, microcarrier) of cell inoculation / attachment on semi-solid / solid matrix is not within the scope of 3D suspension culture of the present invention. In 3D suspension culture of the present invention, the cells grown in the liquid culture medium mainly rely on the interaction with each other to gradually form cell clusters, aggregates and / or spheroids. A variety of suspension culture systems that can be used for ES and iPSC three-dimensional culture are known in the art, which are also suitable for the 3D reprogramming method of the present invention. The 3D suspension culture systems that can be mentioned include, but are not limited to, roller bottles, orbital shakers, fluid systems, for example, roller bottle bioreactors, rotary bioreactors, microfluidic bioreactors, hollow fiber systems. The general principle of the 3D suspension culture system based on the bioreactor is to fill the chamber with a cell suspension with a suitable cell density and provide continuous stirring by stirring, rotating, or using a pump system to perfuse the culture medium. Preferably, in the method of the present invention, a stirring or rotating suspension culture system is used, for example, a stirring or rotating suspension bioreactor, for example, a 100ml to 1 liter stirred suspension rotary suspension bioreactor. In the 3D suspension culture according to the present invention, the size of the cell aggregates suspended in the liquid culture medium can be controlled and maintained by adjusting the stirring or rotation speed, and / or by fluid shear stress, the pluripotency state of the cells and the suppression of undesirable differentiation can be regulated.
[0119] In some embodiments, step (c) of the method of the present invention comprises culturing the MET reprogramming intermediate according to the present invention in a stirred or rotating suspension culture system, e.g., a roller bottle, an orbital shaker, or a bioreactor. In some embodiments, step (c) of the method of the present invention comprises culturing the reprogramming intermediate in suspension at a rotation speed of 30-100 rpm, preferably at a rotation speed of about 60 rpm, about 70 rpm, about 80 rpm, or about 90 rpm.
[0120] In some embodiments, step (c) of the inventive method also includes, after a period of suspension culture, the cell spheroid formed is passaged for at least one generation, preferably at least 2 generations, 3 generations, to obtain a stable iPSC colony. In some embodiments, the size of the iPSC sphere reaches between 300-500um, and cell passage is carried out. In some embodiments, cells are passaged once every 4-6 days, and preferably, in the first 12-48 hours (preferably 24 hours) of cell passage, a ROCK inhibitor, preferably Y27632, is added to the culture medium. In other embodiments, cell passage includes, from the iPSC sphere, producing a single cell or a cell mass of no more than 200 cells, and re-seeding. When passaged, cells can be dissociated into single cells or small cell clusters, for example, dissociated into single cell suspensions, by enzymatic or mechanical means. Any enzyme preparation known in the art that allows cells to be dissociated into single cells can be used. In one embodiment of the invention, the dissociating agent is selected from trypsin / EDTA, TrypLE-Select, collagenase IV and dispersase. Preferably, iPSC single-cell suspensions are generated from iPSC spheres by enzymatic dissociation (eg, Accutase enzyme) for cell passaging.
[0121] The liquid culture medium used for the suspension culture of the present invention is not limited. In some embodiments, the liquid culture medium according to the present invention is a non-gel liquid culture medium. Any liquid culture medium suitable for iPSC culture can be used for the 3D suspension culture according to the present invention. Examples of such culture media are known in the art and include, but are not limited to, StemScale PSC Suspension Medium; 2) mTeSR TM 3D Media for Human PSC Suspension Culture; 3) Essential 8 medium; 4) StemFit Medium; 5) mTeSR TM 3D Media; 6) StemMACS TM iPS-Brew XF;7)RSeT TMIn some embodiments, the method according to the present invention includes, in step (c), using StemScale PSC suspension medium for cell culture.
[0122] Detection of induced pluripotent stem cells
[0123] Pluripotent stem cells (PSCs) are undifferentiated cells with a shortened cell cycle, a characteristic gene expression profile, and the ability to self-renew and give rise to all cell types of the body except those of the extraembryonic lineage. The quality and / or quantity of the obtained 3D-iPSC spheres can be assessed using methods for PSC identification known in the present invention or described in the Examples.
[0124] Characteristics of cell pluripotency include, but are not limited to, detectable morphological features, expression of molecular markers associated with pluripotency and / or biochemical changes, and DNA methylation profiles. These features can be monitored individually or in combination to assess the quality of 3D-iPSC cells. In some embodiments, the features to be evaluated include, but are not limited to: i) round and flat pluripotent stem cell morphology; ii) expression of pluripotent stem cell markers, including SSEA3 / 4, TRA1-60 / 81, TRA1-85, TRA2-54, GCTM-2, TG343, TG30, CD9, CD29, CD133 / prominin, CD140a, CD56, CD73, CD105, CD31, CD34, OCT4, Nanog and / or Sox2, and combinations thereof; iii) the ability to promote germline transmission in mouse chimeras; iv) teratoma formation; vi) embryoid body formation and tri-lineage differentiation in vitro; and vii) reactivation of inactivated X chromosomes.
[0125] In some embodiments, the quality and / or quantity of 3D-iPSCs are assessed by microscopic examination of the morphology of 3D-iPSC spheres or by reseeding them on 2-dimensional culture plates and detecting their growth morphology. In other embodiments, the reprogramming state of iPSC spheres is assessed by detecting the expression of pluripotency markers and / or transgenes in iPSC spheres by immunofluorescence staining and RT-PCR for pluripotency markers. Preferably, the pluripotency markers are selected from one or more of the following: OCT4, SOX2, TRA1-60, NANOG, and PODXL. In addition, live cell staining known in the art can also be used to observe iPSC colonies generated in 3D culture, including, for example, alkaline phosphatase live cell staining; or live cell staining with Tra1-60 or Tra1-81 antibodies that specifically target the iPSC surface marker PODXL, wherein the antibodies can recognize undifferentiated iPSCs and allow identification of reprogrammed cells from various human cell types. In some embodiments, the tri-lineage differentiation capacity of the obtained 3D-iPSC spheres is assessed using methods known in the present invention or described in the Examples.
[0126] The human 3D-iPS cells obtained according to the 3D reprogramming method of the present invention have the potential for unlimited proliferation in vitro. In some embodiments, the human 3D-iPS cells according to the present invention have a morphology close to that of embryonic stem cells when cultured in 2 dimensions in vitro: the cells are round, with large nuclei and relatively small cytoplasmic volumes, and form compact, flat cell colonies similar to ES. In some embodiments, the human 3D-iPS cells according to the present invention express multiple pluripotency markers, selected from, for example, Nanog protein, SSEA-like proteins, and TRA-like proteins. In some embodiments, the human 3D-iPS cells according to the present invention have the potential to differentiate into cells or tissues of the three germ layers. In some embodiments, the human 3D-iPS cells according to the present invention can generate teratomas after being injected into immunodeficient animal individuals.
[0127] In some preferred embodiments, the 3D-iPSC cells according to the present invention have a flat, round colony morphology, combined expression of OCT4, SOX2, NANOG, and PDOXL, and have tri-lineage differentiation capacity in vitro.
[0128] Application of the method of the present invention
[0129] Because the use of iPSCs can avoid most of the ethical and practical issues associated with the large-scale clinical use of ES cells, and patients with iPSC-derived autologous transplants may not require lifelong immunosuppressive therapy to prevent transplant rejection, iPSCs hold great promise for applications in regenerative medicine.
[0130] In another aspect of the present invention, a method for producing downstream cell-derived products is provided. In some embodiments, the method comprises: obtaining 3D-iPSCs by the 3D reprogramming method of the present invention, and using the iPSCs to produce downstream cell-derived products.
[0131] The downstream cell-derived products according to the present invention can be used for the research and development of stem cells, including but not limited to, preventive or therapeutic applications. For example, in some embodiments, the cells of the present invention (3D-iPSC cells or directed differentiated cells induced therefrom) are introduced into individuals in need thereof, including but not limited to individuals in need of regenerating organs, tissues, or cell types. In some embodiments, the cells are genetically modified before they are introduced into an individual.
[0132] In some embodiments, the pluripotent cells produced according to the methods of the present invention are subsequently induced to form downstream cell-derived products selected from the following: for example, hematopoietic (stem / progenitor) cells, neural (stem / progenitor) cells (and optionally more differentiated cells, such as subtype-specific neurons, oligodendrocytes, etc.), pancreatic cells (e.g., endocrine progenitor cells or pancreatic hormone-expressing cells), hepatocytes, cardiovascular (stem / progenitor) cells (e.g., cardiomyocytes, endothelial cells, smooth muscle cells), retinal cells, etc.
[0133] A variety of methods are known for inducing pluripotent stem cells to differentiate into desired cell types. A non-limiting list of recent patent publications describing methods for inducing stem cell differentiation into different cell fates is as follows: U.S. Patent Publication Nos. 2007 / 0281355; 2007 / 0269412; 2007 / 0264709; 2007 / 0259423; 2007 / 0254359; 2007 / 0196919; 2007 / 0172946; 2007 / 0141703; 2007 / 0134215.
[0134] By introducing the pluripotent cells or directed differentiated cells obtained by the methods of the present invention and optionally targeting them to specific injured tissues, a wide range of diseases can be ameliorated. Examples of such diseases include, but are not limited to, neurodegenerative diseases, cerebral infarction, myocardial infarction, heart failure, chronic obstructive pulmonary disease, emphysema, interstitial lung disease, and renal insufficiency. Example
[0135] Materials and methods
[0136] Material
[0137] StemScale PSC Suspension Medium (ThermoFisher, #A4965001)
[0138] Y27632 (Tocris, #1254)
[0139] Essential 8 TM Culture medium (ThermoFisher, #A1517001)
[0140] Penicillin-Streptomycin (P / S) (ThermoFisher, #15140122)
[0141] GlutaMAX supplement (ThermoFisher, #35050061)
[0142] L-glutamine (ThermoFisher, #25030081)
[0143] β-Mercaptoethanol (ThermoFisher, #21985023)
[0144] IL-3 (Miltenyi Biotec, #130-095-070)
[0145] IL-6 (Miltenyi Biotec, #130-093-932)
[0146] SCF(Miltenyi Biotec,#130-096-695)
[0147] FLT3L (Miltenyi Biotec, #130-096-477)
[0148] DPBS (ThermoFisher, #14190-144)
[0149] Accutase(Stem Cell Technologies,#07922)
[0150] StemPro TM -34SFM(1X)(ThermoFisher,#10639011)
[0151] Dulbecco's modified Eagle's medium (DMEM) (ThermoFisher, #11960044)
[0152] Medium 106 (ThermoFisher, #M106500)
[0153] Vitronectin (VTN-N) (ThermoFisher, #A14700)
[0154] Fetal bovine serum (FBS) (HyClone, #SH30071.03)
[0155] Sodium pyruvate (ThermoFisher, #11360070)
[0156] MEM non-essential amino acid solution (NEAA) (ThermoFisher, #11140050)
[0157] Trypsin / EDTA solution (TE) (ThermoFisher, #R001100)
[0158] UltraPure 0.5M EDTA, pH 8.0 (ThermoFisher, #15575020)
[0159] CytoTune 2.0 Sendai Virus Reprogramming Kit (ThermoFisher, #A16517)
[0160] method
[0161] Using CytoTune TM 2.0 Sendai reprogramming kit, according to the manufacturer's instructions and previously published studies 17-19 Human peripheral blood mononuclear cells (PBMC) and fibroblasts were cultured for reprogramming. Briefly, human PBMCs or fibroblasts were seeded into the wells of a multi-well plate approximately 2-3 days before reprogramming transfection and cultured to ensure that the cells were fully adherent and spread. On day 0 of reprogramming (i.e., the day of transfection), CytoTune was used to TM Human PBMCs and fibroblasts were transduced with the 2.0 Sendai vectors KOS, hc-Myc, and hKlf4 at a multiplicity of infection of 5:5:3 or 5:5:6, respectively. Transduced PBMCs and fibroblasts were cultured according to the manufacturer's instructions until day 18-21 of reprogramming. 19 Afterwards, the culture plate was treated with enzymes or EDTA, all cells were harvested, and single-cell suspensions were formed, which were then subjected to the 3D reprogramming procedure of the present invention and the conventional 2D reprogramming procedure as a control.
[0162] 3D Reprogramming Procedure:
[0163] 3D-iPSC establishment:
[0164] In the 3D reprogramming procedure of the present invention, reprogramming intermediates undergoing mesenchymal-epithelial (MET) transition on days 13-21 can be harvested and directly transferred into liquid culture for 3D culture to stabilize and generate iPSC spheres.
[0165] Specifically, the 21-day reprogramming intermediates were harvested and cultured in complete StemScale PSC suspension medium on a rotating suspension culture system. To establish 3D-iPSC spheres, the cultures were subcultured every 4-6 days at a 1:1 ratio, as described below. Near the end of passage 3, stably proliferating 3D-iPSC spheres ranging in size from 300 to 500 μm gradually emerged in the culture, and 3D-iPSC spheres were maintained as described below.
[0166] Maintenance of 3D-iPSC spheroids:
[0167] For maintenance of 3D-iPSC spheroids, culture cells in complete StemScale-PSC suspension medium on an orbital shaker at 70 rpm. Passage cells every 4-6 days using Accutase and reseeding at a cell density of 1 x 10 5 cells / ml; in the first 24 hours after passaging, the culture medium was supplemented with 10 uM Y27632. The culture medium was changed daily, in which 50% of the spent medium was removed and replaced with 50% fresh complete StemScale-PSC suspension medium.
[0168] 2-D reprogramming procedure (used as a control)
[0169] Establishment of 2D-iPSCs:
[0170] In conventional 2D reprogramming procedures, the reprogramming intermediates of day 18-21 are harvested and 2D culture is continued on Vitronectin (ThermoFisher) in Essential 8 culture medium to establish 2D-iPSC cultures (i.e., P0 generation 2D-iPSC cultures). According to the method described in the conventional maintenance of 2D-iPSC below, the culture is passaged once every 4 days. Typically at about the 3rd generation (P3), stable 2D-iPSC cultures are established.
[0171] Routine maintenance of 2D-iPSCs:
[0172] Cells were passaged every 4 days using 0.5 mM EDTA (ThermoFisher) at a ratio of 1:10-1:20 on plates coated with 5 μg / ml vitronectin (ThermoFisher). During this period, the medium was changed daily, and on the first day of passage, the medium was supplemented with 10 μM Y-27632 (ROCK inhibitor).
[0173] result:
[0174] Morphological characterization of reprogramming intermediates
[0175] On reprogramming days 0, 7, and 35, morphological changes of reprogrammed cells in 2D culture were monitored under a phase contrast microscope to observe the morphology of reprogramming intermediates. The results are shown in Figure 1.
[0176] As shown in Figure 1 , during the reprogramming process, cells undergo obvious morphological changes.
[0177] The left image (A) shows that cells on reprogramming day 0 exhibit the typical cell morphology of fibroblasts (somatic cells) with an elongated spindle shape.
[0178] The middle figure (B) shows cells on the 7th day of reprogramming. The white arrows indicate non-reprogrammed / reprogramming-resistant cells, which still maintain a fibroblast-like morphology; the black arrows indicate the reprogramming intermediate area (black coil area), and the cell colonies exhibit a dome-shaped morphology. The bright round cells are tightly packed together and have lost their fibroblast-like morphology.
[0179] The right panel (C) shows a stable iPSC culture established after passage. As can be seen from the figure, the morphology of the stable iPSC culture differs from that of the reprogramming intermediate in that the cell colonies of the former are much flatter and have smaller cells, while the cells in the colonies remain densely packed.
[0180] Characterization of 3D reprogrammed iPSC spheroids
[0181] The morphology of 3D-reprogrammed iPSC spheres was assessed using phase contrast microscopy, and cell counts were performed using a trypan blue-based automated cell counter. The expression of multiple pluripotency markers in 3D-reprogrammed iPSC spheres was evaluated using immunostaining and qRT-PCR analysis. The tri-lineage differentiation capacity of 3D-reprogrammed iPSCs was assessed using the STEMdiff™ Trilineage Differentiation Kit, and the differentiation efficiency into endoderm, mesoderm, and ectoderm was analyzed using flow cytometry.
[0182] 3D reprogrammed iPSC spheroid morphology assessment and cell counting
[0183] The results of morphological characterization of 3D reprogrammed iPSC spheres are shown in Figure 2 A. Figure 2 A shows representative images of iPSCs generated by the 2D reprogramming method and iPSCs generated from the 3D reprogramming method.
[0184] After 10 passages of the iPSCs generated by the 2D reprogramming method and the iPSCs generated by the 3D reprogramming method, the same number of iPSC cells were taken and cultured on a 6-well plate in an adherent or suspended manner for 4 days. Accutase digestion was used to harvest the iPS single cell suspension, and cell counting was performed using an automatic cell counting method based on trypan blue. Figure 2B shows the cell yield of the 2D reprogramming method and the 3D reprogramming method after 4 days of iPSC expansion. Compared with the 2D method, the iPSCs generated and maintained using the 3D method of the present invention achieved approximately 2 times higher iPSC yield in a very short time of suspension culture.
[0185] Immunostaining
[0186] Immunostaining of 2D-iPSCs and 3D-iPSCs was performed as follows. Cells were fixed in 4% paraformaldehyde (PFA, Sigma) for 30 minutes at room temperature, then permeabilized with 0.5% Triton X-100 (Sigma) in DPBS (ThermoFisher) for 30 minutes at room temperature and blocked with blocking buffer (3% bovine serum albumin (BSA) (Sigma) + 0.1% Tween-20 (Sigma) in Dulbecco's phosphate-buffered saline (DPBS; ThermoFisher)) for 30 minutes at room temperature. All antibodies used for immunostaining were prepared in blocking buffer. Primary antibodies were incubated overnight on a shaker at 4°C, followed by incubation with secondary antibodies (1:500 dilution in blocking buffer) for 1-2 hours at room temperature. After antibody labeling, cells were stained with 4',6-diamidino-2-phenylindole dihydrochloride (DAPI, ThermoFisher) at a concentration of 5 μg / ml in blocking buffer for 10 minutes. Subsequently, cells were imaged under an inverted microscope or an inverted confocal microscope (Leica).
[0187] The primary antibodies used in this experiment include: 1) mouse anti-OCT3 / 4 IgG2b (Santa Cruz Biotechnology Cat#sc-5279); 2) rat anti-SOX2 IgG2a (Invitrogen Cat#14-9811-82); and 3) mouse anti-TRA-1-60 IgM (BD Biosciences Cat#560071).
[0188] The results are shown in Figure 3. Figure 3 shows representative images of 2D and 3D reprogrammed iPSCs, where pluripotency markers OCT4, SOX2, and TRA-160 were immunostained. 3D reprogrammed iPSCs were generated using (A) peripheral blood mononuclear cells (PBMCs) and (B) fibroblasts as the starting somatic cell sources for reprogramming. 3D reprogrammed iPSCs (bottom panel) exhibited a compact spherical morphology and, similar to 2D reprogrammed iPSCs (top panel), also expressed pluripotency markers OCT4, SOX2, and TRA-160.
[0189] RT-qPCR analysis
[0190] RNA was extracted using the RNeasy micro kit (Qiagen, #74004) and QIAcube (Qiagen) according to the manufacturer's instructions. Reverse transcription was performed using the QuantiTect Reverse Transcription Kit (Qiagen, #205311). Real-time PCR reactions were set up in duplicate using the QuantiFast SYBR Green PCR Kit (Qiagen, #204057) and detected on a real-time PCR detection system. The GAPDH housekeeping gene was used as a control to calculate the relative expression of each pluripotency marker and Sendai virus transgene. The primers used for RT-qPCR analysis are as follows: Primers used for RT-qPCR analysis
[0191] The results are shown in Figure 4. Figure 4A shows qRT-PCR analysis for the detection of the Sendai virus transgene. No Sendai virus transgene or exogenous reprogramming factors were detected in the established 3D-reprogrammed iPSCs. Figure 4B shows qRT-PCR analysis of pluripotency marker expression. Compared to corresponding somatic cell controls, 3D-reprogrammed iPSCs highly expressed the pluripotency markers OCT4, SOX2, NANOG, and PODXL.
[0192] Trilineage differentiation assay
[0193] Using STEMdiff three-lineage differentiation kit (Stem Cell Technologies, #05230), according to the manufacturer's instructions, the three-lineage differentiation ability determination of 2D-iPSC and 3D-iPSC is carried out.For the flow cytometric analysis of differentiated cells, TrypLE Express cells are harvested, and Foxp3 / transcription factor staining buffer kit (ThermoFisher, #00-5523-00) is used, according to the manufacturer's instructions, the fixation and permeabilization of cells are carried out.Then, using a two-step antibody labeling procedure, cells are stained, wherein in each labeling step, cells are stained on ice for 30 minutes, with a DPBS washing step between the two steps.Cell analysis is carried out on BD LSR Fortessa Analyzer (BD Biosciences).
[0194] Antibodies used for the above flow cytometry analysis include:
[0195] 1) Rat anti-Nestin (Abcam, Cat#ab6142); 2) Mouse anti-PAX6 IgG1 (DHSB, Cat#Pax6); 3) Anti-SOX17 antibody (AbCam, Cat#224637); 4) Rat anti-FOXA2 (Abcam, Cat#ab256493); 5) Mouse anti-CXCR4 IgG2a (PE Miltenyi Biotec, Cat#130-117-690); and 6) Brachyrury monoclonal antibody (Cell signaling technology, Cat#81694s).
[0196] Figure 5 shows the tri-lineage differentiation potential of 3D-reprogrammed iPSCs. (A) shows that 3D-reprogrammed iPSCs can differentiate into endoderm (SOX17+ / FOXA2+) and ectoderm (PAX6+ / NESTIN+) at higher efficiency than 2D-reprogrammed iPSCs, and differentiate into mesoderm (Brachyury+ / CXCR4+) at comparable efficiency. (B) shows representative FACS analysis of endoderm, mesoderm, and ectoderm generated by 2D- and 3D-reprogrammed iPSCs.
[0197] References
[0198] 1. Thomson, JA et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145–1147 (1998).
[0199] 2.Takahashi,K.et al.Induction of pluripotent stem cells from adult human fibroblasts by defined factors.Cell 131,861–872(2007).
[0200] 3.Yamanaka,S.Pluripotent stem cell-based cell therapy-promise and challenges.Cell Stem Cell 27,523–531(2020).
[0201] 4.Omole,A.E.&Fakoya,A.O.J.Ten years of progress and promise of induced pluripotent stem cells:historical origins,characteristics,mechanisms,limitations,and potential applications.PeerJ 6,e4370(2018).
[0202] 5.Warren,L.et al.Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA.Cell Stem Cell 7,618–630(2010).
[0203] 6.Carey,B.W.et al.Reprogramming of murine and human somatic cells using a single polycistronic vector.Proc.Natl.Acad.Sci.U.S.A.106,157–162(2009).
[0204] 7.Kim,D.et al.Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins.Cell Stem Cell 4,472–476(2009).
[0205] 8.Zhou,H.et al.Generation of induced pluripotent stem cells using recombinant proteins.Cell Stem Cell 4,381–384(2009).
[0206] 9.Okita,K.et al.A more efficient method to generate integration-free human iPS cells.Nat.Methods 8,409–412(2011).
[0207] 10.Yu,J.et al.Induced pluripotent stem cell lines derived from human somatic cells.Science 318,1917–1920(2007).
[0208] 11.Caiazzo,M.et al.Defined three-dimensional microenvironments boost induction of pluripotency.Nat.Mater.15,344–352(2016).
[0209] 12.Caiazzo,M.,Tabata,Y.&Lutolf,M.P.Generation of induced pluripotent stem cells in defined three-dimensional hydrogels.Methods Mol.Biol.1612,65–78(2017).
[0210] 13.Borys,B.S.et al.Optimized serial expansion of human induced pluripotent stem cells using low-density inoculation to generate clinically relevant quantities in vertical-wheel bioreactors.Stem Cells Transl.Med.9,1036–1052(2020).
[0211] 14.Nogueira,D.E.S.et al.Strategies for the expansion of human induced pluripotent stem cells as aggregates in single-use Vertical-Wheel TM bioreactors.J.Biol.Eng.13,74(2019).
[0212] 15.Lei,Y.&Schaffer,D.V.A fully defined and scalable 3D culture system for human pluripotent stem cell expansion and differentiation.Proc.Natl.Acad.Sci.U.S.A.110,E5039-48(2013).
[0213] 16.Rohani,L.et al.Stirred suspension bioreactors maintain pluripotency of human pluripotent stem cells.Commun.Biol.3,492(2020).
[0214] 17.Liu,X.et al.Comprehensive characterization of distinct states of human naive pluripotency generated by reprogramming.Nat.Methods 14,1055–1062(2017).
[0215] 18.Tong,J.et al.Generation of four iPSC lines from peripheral blood mononuclear cells(PBMCs)of an attention deficit hyperactivity disorder(ADHD)individual and a healthy sibling in an Australia-Caucasian family.Stem Cell Res.34,101353(2019).
[0216] 19.CytoTune TM -iPS 2.0 Sendai Reprogramming Kit.https: / / www.thermofisher.com / order / catalog / product / A16517.
Claims
1. A method for generating iPSCs by reprogramming somatic cells, the method comprising the following steps: (a) performing a reprogramming treatment on somatic cells to allow the somatic cells to contact with reprogramming factors; (b) culturing the treated somatic cells of step (a) under 2D culture conditions for a period of time sufficient to obtain a reprogramming intermediate, wherein the reprogramming intermediate is characterized in that at least 20%, 30%, 40% or 50% of the cells are iPSC precursor cells that have undergone MET transformation; (c) harvesting the reprogramming intermediates of step (b), and culturing them in liquid culture medium under 3D suspension culture conditions to form reprogrammed iPSC spheres, Wherein, the somatic cells are somatic cells from non-human primates or humans.
2. The method according to claim 1, wherein The iPSC precursor cells that have undergone MET transformation lose the morphological characteristics of the original somatic cells and present a MET morphology characterized by dome-shaped dense cell colonies and optionally an increased nuclear-to-cytoplasmic ratio.
3. A method according to claims 1-2, wherein The iPSC precursor cells that have undergone MET transformation express pluripotency markers, TRA-1-60 and / or SSEA3.
4. The method according to claims 1-3, wherein step (c) comprises harvesting the reprogramming intermediates on about day 7 to about day 21 of reprogramming, more preferably on about day 10 to about day 18 of reprogramming, for example, on day 10, day 11, day 12, day 13, day 14, day 15, day 16, day 17, day 18.
5. A method according to claims 1-4, wherein The somatic cell is a somatic cell or a cell line from an adult individual.
6. The method according to claims 1-5, wherein the somatic cells are human blood cells, such as human PBMCs.
7. The method according to claims 1-5, wherein the somatic cells are human fibroblasts.
8. A method according to claims 1 to 7, wherein In step (c), the 3D suspension culture is a stirring or rotating suspension culture system, such as a roller bottle, an orbital shaker or a bioreactor.
9. A method according to claims 1 to 8, wherein Step (c) further comprises, after a period of suspension culture, subculturing the formed cell spheres for at least one generation, preferably at least 2 or 3 generations, to obtain a stable iPS cell population.
10. A method according to claims 1 to 9, wherein The reprogramming factors are reprogramming transcription factors, and in step (a), one or more reprogramming factors or nucleic acids encoding the reprogramming factors are introduced into the somatic cells to increase the expression or protein amount of the reprogramming factors in the somatic cells.
11. A method according to claims 1 to 10, wherein: Step (a) comprises delivering the reprogramming factor to the somatic cell in the form of an integrating virus or a non-integrating virus, or in the form of mRNA, an episomal plasmid or a protein, Preferably, step (a) comprises delivering reprogramming factors to the somatic cells using a non-integrating virus, particularly a Sendai virus vector.
12. A method according to claims 1 to 11, wherein The one or more reprogramming factors include or consist of at least three or at least four of Klf4, c-Myc, Oct3 / 4, Sox2, Nanog and Lin28; Preferably, the one or more reprogramming factors include or consist of Oct3 / 4, Sox2, c-Myc and Klf4.
13. A method according to claims 1 to 12, wherein: Step (c) comprises culturing the reprogramming intermediate in suspension at a rotation speed of 30-100 rpm, preferably, at a rotation speed of about 70 rpm.
14. A method according to claims 1 to 13, wherein: In step (c), the 3D culture is performed using iPSC maintenance medium (preferably, StemScale PSC suspension medium).
15. A method for maintaining or expanding 3D reprogrammed iPSCs, comprising: (i) obtaining reprogrammed iPSC spheres from autologous cells according to the method of claims 1-14; as well as (ii) Maintaining or expanding iPSCs in 3D suspension culture conditions.
16. The method according to claim 15, wherein: The method further comprises a cell passaging step after step (i) and before step (ii).
17. A method according to claims 15-16, wherein: When the size of the iPSC sphere reaches between 300-500 um, cell passaging is performed.
18. A method according to claims 15-17, wherein: The iPSC maintenance culture includes subculturing cells once every 4-6 days, Preferably, a ROCK inhibitor, preferably Y27632, is added to the culture medium during the first 12-48 hours (preferably 24 hours) of cell passage.
19. A method according to claims 15-18, wherein: The cell passaging includes generating single cells or cell aggregates of no more than 200 cells from iPSC spheres and reseeding; Preferably, iPSC single cell suspension is generated from iPSC spheres by enzymatic dissociation (eg, Accutase enzyme) for cell passaging.
20. A method for producing a downstream cell-derived product, the method comprising: iPSCs are obtained by the method of any one of claims 1 to 19, and downstream cell-derived products are produced using the iPSCs.
Citation Information
Patent Citations
Method for efficiently inducing reprogramming of human body cells into pluripotent stem cells
CN102093981A
Method for efficiently preparing CD44 gene defect mouse induced pluripotent stem cells
CN103695469A
Pluripotent stem cell inducer and application thereof
CN108998417A
Composition, culture medium and method for inducing reprogramming of human cells into induced pluripotent stem cells
CN112831462A
